ANAB Stock Analysis: Buy, Sell, or Hold?
ANAB - AnaptysBio, Inc. Common Stock
$53.36
-1.68 (-3.05%)
▼
5d:
-1.46%
30d:
-18.45%
90d:
-18.82%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
1d
Get Alerted When ANAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ANAB shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: ANAB shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$82.16
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$51.02
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ANAB is currently trading at $53.36, which is considered oversold relative to its 30-day fair value range of $53.40 to $65.47. The stock's valuation (Forward PE: 10.2) is in line with its historical norms (11.2). Remarkably, the market is currently pricing in an annual earnings decline of 3.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ANAB is in a downtrend. Immediate support is located at $49.71, while resistance sits at $59.09. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $87.09 (+63.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ANAB is in a downtrend. Immediate support is located at $49.71, while resistance sits at $59.09. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $87.09 (+63.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$53.40 -
$65.47
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.1%)
- BULLISH: Trading 63.2% below Wall St target ($87.09)
Trading Range Analysis
30-Day Trading Range
$53.40 -
$65.47
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$5.67
(10.6%)
Support & Resistance Levels
Support Level
$49.71
Resistance Level
$59.09
Current Trend
Downtrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.19
Wall Street Target
$87.09
(+63.2%)
Revenue Growth (YoY)
-8.0%
Profit Margin
-11.5%
Valuation Discount vs History
-3.1% cheaper
PE vs Historical
10.2 vs 11.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.1%
(market-implied from PE analysis)
1-Year Target
$51.71
(-3%)
2-Year Target
$50.10
(-6%)
3-Year Target
$48.55
(-9%)
3-Yr Target (if PE normalizes)
(PE: 10→11)
$53.35
(0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.2 to 11.2
Stabilization Target:
$58.64
(+9.9%)
PE Expansion Potential:
+9.9%
Share & Embed Analysis
Last updated: August 03, 2026 12:59 AM ET
Data refreshes hourly during market hours. Next update: 1:59 AM
Data refreshes hourly during market hours. Next update: 1:59 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
John P Schmid
SELL
20645 shares
2026-03-30
Daniel Faga
SELL
17679 shares
2026-03-27
Eric J Loumeau
SELL
10000 shares
2026-02-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 49 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 57 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 58 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 59 HOLD |